Requirement for safety monitoring for approved MS therapies - An overview. Rommer PS, Zettl UK, Kieseier B, Hartung H-P, Menge T, Frohman E, Greenberg BM, Hemmer B, Stüve O Clin Exp Immunol. 2013 Sep 17. PMID: 24102425. Abstract CommentRecommendBookmarkWatch